Effective Treatment of Advanced Breast Cancer with Vinorelbine and Other Drugs
Author Information
Author(s): GV Komek, K Haider, W Kwasny, F Lang, G Krauss, M Hejnal, M Raderer, G Weinlinder, D Depisch, W Scheithauer
Primary Institution: Vienna University Medical School
Hypothesis
The study investigates the efficacy and tolerance of vinorelbine, 5-fluorouracil, and leucovorin plus G-CSF in advanced breast cancer.
Conclusion
The combination of vinorelbine, 5-fluorouracil, and leucovorin plus G-CSF is an effective first-line treatment for advanced breast cancer with modest overall toxicity.
Supporting Evidence
- The overall response rate was 59% for chemotherapeutically naive patients.
- Median time to progression was 10.5 months in previously untreated patients.
- Granulocytopenia was the most frequent and dose-limiting side effect.
Takeaway
Doctors tested a new medicine for women with advanced breast cancer, and it helped many of them feel better without making them too sick.
Methodology
A phase II trial was conducted with 53 patients receiving a combination of vinorelbine, 5-fluorouracil, leucovorin, and G-CSF.
Limitations
The study had a small sample size and was limited to patients aged 75 years or younger.
Participant Demographics
Median age was 55 years, with a range of 29-75 years; 37 patients were previously untreated.
Statistical Information
Confidence Interval
95% confidence interval 42-75%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website